AU2016256573B2 - Imidazopyrazinones as PDE1 inhibitors - Google Patents
Imidazopyrazinones as PDE1 inhibitors Download PDFInfo
- Publication number
- AU2016256573B2 AU2016256573B2 AU2016256573A AU2016256573A AU2016256573B2 AU 2016256573 B2 AU2016256573 B2 AU 2016256573B2 AU 2016256573 A AU2016256573 A AU 2016256573A AU 2016256573 A AU2016256573 A AU 2016256573A AU 2016256573 B2 AU2016256573 B2 AU 2016256573B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyrazin
- imidazo
- pyran
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CI*(C1)*1C(N(C*)C1=C)=C(*)[n]2c1cnc2C=C* Chemical compound CI*(C1)*1C(N(C*)C1=C)=C(*)[n]2c1cnc2C=C* 0.000 description 4
- JQTZXVDGXPKTCX-UHFFFAOYSA-N CC(C)(C)OC(NCc(ncc(C)n1)c1OC)=O Chemical compound CC(C)(C)OC(NCc(ncc(C)n1)c1OC)=O JQTZXVDGXPKTCX-UHFFFAOYSA-N 0.000 description 1
- JCIBBUBJEGSSFD-UHFFFAOYSA-N CC(C[n]1c(C(C)=O)cnc1)=O Chemical compound CC(C[n]1c(C(C)=O)cnc1)=O JCIBBUBJEGSSFD-UHFFFAOYSA-N 0.000 description 1
- AXHZNUDHLGMSHQ-UHFFFAOYSA-N CC(NC1=O)=C[n]2c1cnc2C1CCOCC1 Chemical compound CC(NC1=O)=C[n]2c1cnc2C1CCOCC1 AXHZNUDHLGMSHQ-UHFFFAOYSA-N 0.000 description 1
- POYSMFHSSMDVSW-UHFFFAOYSA-N CCC(C)(C)c1ncc2[n]1C=C(C)N(Cc(cc1)ccc1OC)C2=C Chemical compound CCC(C)(C)c1ncc2[n]1C=C(C)N(Cc(cc1)ccc1OC)C2=C POYSMFHSSMDVSW-UHFFFAOYSA-N 0.000 description 1
- BWSAQFJBDAROHA-UHFFFAOYSA-N CCCc1ncc2[n]1C=C(C)N(Cc(cc1)ccc1OC)C2=C Chemical compound CCCc1ncc2[n]1C=C(C)N(Cc(cc1)ccc1OC)C2=C BWSAQFJBDAROHA-UHFFFAOYSA-N 0.000 description 1
- ZGTNMSAWMPQSKF-INIZCTEOSA-N C[C@@H](COCC1)N1c1ncc2[n]1C=C(C)N(Cc(cc1)ccc1OC)C2=C Chemical compound C[C@@H](COCC1)N1c1ncc2[n]1C=C(C)N(Cc(cc1)ccc1OC)C2=C ZGTNMSAWMPQSKF-INIZCTEOSA-N 0.000 description 1
- ZMDAOENOXNPQSX-UHFFFAOYSA-N Cc1nc(OC)c(CNC(C2CCOCC2)=O)nc1 Chemical compound Cc1nc(OC)c(CNC(C2CCOCC2)=O)nc1 ZMDAOENOXNPQSX-UHFFFAOYSA-N 0.000 description 1
- NTXQTICQWIKNOO-UHFFFAOYSA-N O=C1N(Cc2cc(F)ccc2)C(Cc2ccccc2)=C[n]2c1cnc2C1CCOCC1 Chemical compound O=C1N(Cc2cc(F)ccc2)C(Cc2ccccc2)=C[n]2c1cnc2C1CCOCC1 NTXQTICQWIKNOO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500261 | 2015-04-30 | ||
| DKPA201500261 | 2015-04-30 | ||
| DKPA201500666 | 2015-10-29 | ||
| DKPA201500666 | 2015-10-29 | ||
| DKPA201600202 | 2016-04-04 | ||
| DKPA201600202 | 2016-04-04 | ||
| PCT/EP2016/059583 WO2016174188A1 (en) | 2015-04-30 | 2016-04-29 | Imidazopyrazinones as pde1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016256573A1 AU2016256573A1 (en) | 2017-12-14 |
| AU2016256573B2 true AU2016256573B2 (en) | 2019-11-21 |
Family
ID=55910242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016256573A Ceased AU2016256573B2 (en) | 2015-04-30 | 2016-04-29 | Imidazopyrazinones as PDE1 inhibitors |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| BR112018013084A2 (pt) | 2016-10-28 | 2018-12-11 | H Lundbeck As | tratamentos de combinação compreendendo a administração de imidazopirazinonas |
| SG11201903770UA (en) * | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| KR102590848B1 (ko) | 2016-12-28 | 2023-10-19 | 다트 뉴로사이언스, 엘엘씨 | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 |
| ES2902365T3 (es) | 2017-11-27 | 2022-03-28 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituidos como inhibidores de PDE1 |
| AR113926A1 (es) * | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| KR20210013214A (ko) | 2018-05-25 | 2021-02-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2020210614A1 (en) | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| EP1626971B1 (de) | 2003-05-09 | 2011-08-10 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
| HRP20090495T1 (hr) * | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
| EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| MX2009011830A (es) | 2007-05-11 | 2009-11-13 | Pfizer | Compuestos amino-heterociclicos. |
| WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) * | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| EA201170772A1 (ru) | 2008-12-06 | 2012-03-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| MX2011005935A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| DK3339323T3 (da) | 2010-08-12 | 2020-01-20 | Lilly Co Eli | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf |
| AU2011305568B2 (en) * | 2010-09-20 | 2015-12-10 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN106905324B (zh) * | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| CN104093720B (zh) | 2012-01-26 | 2017-04-12 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| JP2013166727A (ja) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロイミダゾピラジノン誘導体 |
| CA2877146C (en) | 2012-06-18 | 2020-10-20 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| US9598426B2 (en) | 2013-03-15 | 2017-03-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| TW201609700A (zh) | 2014-02-19 | 2016-03-16 | Ｈ 朗德貝克公司 | ２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶作爲ｂａｃｅ１抑制劑用於治療阿茲海默症 |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US20180244645A1 (en) | 2015-08-12 | 2018-08-30 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
| AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| SG11201903770UA (en) | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| BR112018013084A2 (pt) | 2016-10-28 | 2018-12-11 | H Lundbeck As | tratamentos de combinação compreendendo a administração de imidazopirazinonas |
-
2016
- 2016-04-26 JO JOP/2016/0081A patent/JO3627B1/ar active
- 2016-04-27 TW TW105113074A patent/TWI695838B/zh not_active IP Right Cessation
- 2016-04-29 DK DK16720101.1T patent/DK3288944T3/da active
- 2016-04-29 UA UAA201710625A patent/UA123050C2/uk unknown
- 2016-04-29 ME MEP-2019-186A patent/ME03414B/me unknown
- 2016-04-29 LT LTEP16720101.1T patent/LT3288944T/lt unknown
- 2016-04-29 EP EP16720101.1A patent/EP3288944B1/en active Active
- 2016-04-29 HR HRP20191180TT patent/HRP20191180T1/hr unknown
- 2016-04-29 SM SM20190393T patent/SMT201900393T1/it unknown
- 2016-04-29 JP JP2017556677A patent/JP6663930B2/ja active Active
- 2016-04-29 GE GEAP201614615A patent/GEP20207058B/en unknown
- 2016-04-29 HK HK18111408.3A patent/HK1252098B/en unknown
- 2016-04-29 SG SG11201708822PA patent/SG11201708822PA/en unknown
- 2016-04-29 PL PL16720101T patent/PL3288944T3/pl unknown
- 2016-04-29 HU HUE16720101 patent/HUE044244T2/hu unknown
- 2016-04-29 AU AU2016256573A patent/AU2016256573B2/en not_active Ceased
- 2016-04-29 MA MA41977A patent/MA41977B1/fr unknown
- 2016-04-29 RU RU2017137514A patent/RU2712219C2/ru active
- 2016-04-29 KR KR1020177030665A patent/KR102605759B1/ko active Active
- 2016-04-29 RS RS20190893A patent/RS59051B1/sr unknown
- 2016-04-29 CN CN201680023903.9A patent/CN107531714B/zh active Active
- 2016-04-29 US US15/142,116 patent/US20160318939A1/en not_active Abandoned
- 2016-04-29 WO PCT/EP2016/059583 patent/WO2016174188A1/en not_active Ceased
- 2016-04-29 SI SI201630319T patent/SI3288944T1/sl unknown
- 2016-04-29 ES ES16720101T patent/ES2735422T3/es active Active
- 2016-04-29 PE PE2017002342A patent/PE20180121A1/es unknown
- 2016-04-29 BR BR112017023182-4A patent/BR112017023182B1/pt not_active IP Right Cessation
- 2016-04-29 MY MYPI2017001597A patent/MY182382A/en unknown
- 2016-04-29 TN TNP/2017/000428A patent/TN2017000428A1/en unknown
- 2016-04-29 PT PT16720101T patent/PT3288944T/pt unknown
- 2016-04-29 EA EA201792157A patent/EA031946B1/ru not_active IP Right Cessation
- 2016-04-29 MX MX2017013785A patent/MX375737B/es active IP Right Grant
- 2016-04-29 GE GEAP201914615A patent/GEAP201914615A/en unknown
- 2016-04-29 CA CA2983563A patent/CA2983563A1/en active Pending
-
2017
- 2017-06-06 US US15/615,380 patent/US10011606B2/en active Active
- 2017-10-10 ZA ZA2017/06847A patent/ZA201706847B/en unknown
- 2017-10-12 CO CONC2017/0010399A patent/CO2017010399A2/es unknown
- 2017-10-24 GT GT201700223A patent/GT201700223A/es unknown
- 2017-10-26 CL CL2017002719A patent/CL2017002719A1/es unknown
- 2017-10-27 EC ECIEPI201772228A patent/ECSP17072228A/es unknown
- 2017-10-29 IL IL255316A patent/IL255316B/en unknown
- 2017-10-30 PH PH12017501990A patent/PH12017501990B1/en unknown
- 2017-10-30 DO DO2017000254A patent/DOP2017000254A/es unknown
-
2018
- 2018-06-07 US US16/002,116 patent/US10858362B2/en active Active
-
2019
- 2019-07-15 CY CY20191100751T patent/CY1121806T1/el unknown
-
2020
- 2020-10-26 US US17/079,951 patent/US11472810B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11472810B2 (en) | Imidazopyrazinones as PDE1 inhibitors | |
| US10912773B2 (en) | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | |
| EP3532064B1 (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| WO2016170064A1 (en) | Imidazotriazinones as pde1 inhibitors | |
| HK40005946A (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| HK40005946B (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| OA18771A (en) | Imidazopyrazinones as PDE1 Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |